Dr Reddy's Laboratories (DRL) has sought de-notification of its SEZ at Medak in Andhra Pradesh.
The company is likely to shift its proposed formulations unit at Medak to Visakhapatnam. It has another SEZ for manufacturing Active Pharmaceutical Ingredients (APIs) in Visakhapatnam. The company has given an undertaking to the Union Ministry of Commerce & Industry for refunding the duty benefits availed of in the name of SEZ.
DRL had acquired around 103 ha at Melasangam and Lingampally villages in Medak to set up a tablets and capsules manufacturing unit for exports. In Visakhapatnam, it had acquired around 260 acre for the bulk drugs SEZ, which will now house the formulation SEZ as well. The company is expected invest around $200 million (approx Rs 980 crore) in both the SEZs.
Also See:
Dr. Reddy’s, Fujifilm join hands for generics business in Japan (29-July-11)
